New!
Portfolio
Login
/
Sign Up
Search
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
close
close
Send us Feedback
Abbott Laboratories (ABT)
SUMMARY
BULLS
BEARS
TOPICS
DATA CENTRAL
STOCK CHART
SEC FILINGS
BALANCE
INCOME
CASH FLOW
Key Metrics for ABT as compared to
Top Competitors
Drug Manufacturers - Major
Consumer Products
Drug Manufacturers
Pharma & Healthcare
All values TTM unless otherwise noted (*)
INCOME STATEMENT (
See all
)
Revenue
►
35.8B
EBITDA
►
5.86B
Net Income
►
5.26B
Revenue Growth
►
-8.8%
Net Income Growth
►
3.1%
Operating Margin
►
19.1%
Net Margin
►
14.7%
Revenue, Net Income, and Net Margin
Revenue, Gross Profit, and Gross Margin
Operating Income
Ebit
Income Before Taxes
Net Income from Continuing Ops
Interest vs Continuing Income
Interest Coverage
Operating Expenses
Research & Development
SG&A
Amortization & Depreciation
Please install
Flash Player
to view this chart.
BALANCE SHEET (most recent quarter) (
See all
)
Debt / Equity
►
1.50
Current Ratio
►
1.37
Quick Ratio
►
1.18
Interest Coverage Ratio
►
34.1
Book Value Per Share
►
0
Cash Per Share
►
0
ASSETS
LIABILITIES
Cash
0
Current Liabilities
0
Other Current Assets
0
Long-term Debt
0
Fixed Assets
0
Other Liabilities
0
Other Assets
0
Total Liabilities
0
Total Assets
0
Total Equity
0
INDUSTRY METRICS (
See all
|
Compare across Consumer Products
)
Revenue
►
35.8B
Revenue
Net Income
Operating Income
SEC FILINGS (
See all
)
10-K (Mar 13)
Older:
02/15/13
,
02/21/12
,
02/21/12
,
02/18/11
10-Q (May 13)
Older:
11/07/12
,
11/07/12
,
08/07/12
,
08/07/12
8-K (Apr 13)
Older:
04/17/13
,
04/16/13
,
01/23/13
,
01/07/13
Form 4 (May 13)
Older:
04/30/13
,
04/30/13
,
04/30/13
,
04/30/13
View All Filings for Abbott_Laboratories (ABT)
STOCK SUMMARY
Open
Day Range
-
52 Week Range
-
Volume
Avg Volume (3 mo)
Shares Outstanding
1558864658.00000
Market Cap
EPS
3.38
VALUATION
Price to Earnings (P/E)
►
11.2
Price to Book (P/B)
►
0
Price to Sales (P/S)
►
1.64
Return on Assets (ROA)
►
16.9%
Return on Equity (ROE)
►
41.5%
EV/EBITDA
►
10.0
Dividend Yield
1.5%
ANALYST RECOMMENDATIONS
Please install
Flash Player
to view this chart.
OWNERSHIP
Net Insider Buying 3mo
0%
Net Insider Buying 6mo
0%
Net Insider Buying 1yr
0%
Held by insiders
0.5%
Held by institutions
1.1%
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
〉
Bet you've never seen portfolio analytics like these.
Introducing
SigFig
— from the creators of
Take Tour